BSE Healthcare News and Updates

Name: Latest research reports of Zydus Lifesciences Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Zydus Lifesciences Ltd.
Rating: 5
Author: Geojit BNP Paribas

Keep track of all breaking news on BSE Healthcare from all sources in a single place.

Load latest

Sanofi Consumer Healthcare India Ltd.

17 Apr 2025

4946.20

0.02%

Dividend, bonus, split: Sanofi India, 7 others to go ex-date next week

Business Standard

Here is the complete list of stocks to remain in focus during next week, following the announcement of corporate actions such as dividends, bonus issues, or stock-splits (subdivision)

Number of FII/FPI investors increased from 123 to 136 in Mar 2025 qtr.

GlaxoSmithKline Pharmaceuticals Ltd.

17 Apr 2025

2809.30

-0.22%

Trend turns favourable for GlaxoSmithKline Pharma, key levels to track

Business Standard

GlaxoSmithKline Pharma stock has seen formation of 'Golden Cross' on the daily chart on Thursday; last time the stock saw a similar development, it rallied almost 117% over the next 14 months.

Number of FII/FPI investors decreased from 347 to 340 in Mar 2025 qtr

FDC Ltd.

16 Apr 2025

430.25

-0.08%

CDSCO halts manufacture, sale, distribution of 35 FDCs over safety concerns

Business Standard

The list of unapproved FDCs includes antidiabetics, antibiotics, painkillers, infertility medications and nutritional supplements

FDC Ltd. is trading below its 100 day SMA of 454.4

Narayana Hrudayalaya Ltd.

16 Apr 2025

1835.40

0.65%

Delhi's Barapulla Road shut 12-5 am till Apr 24; NCRTC urges Ring Road use

Business Standard

The Barapulla Road to Maharani Bagh Interchange stretch, along the Delhi-Ghaziabad-Meerut Namo Bharat Corridor, will remain closed to traffic from 12 am to 5 am until April 24 due to ongoing construction work, authorities said on Wednesday. The National Capital Region Transport Corporation (NCRTC) in a statement urged commuters to take alternative routes. Commuters travelling from ITO, NH-24, NH-9, Sarai Kale Khan, and DND towards Maharani Bagh, Sundial, or Siddharth Extension, or on their way to Lala Lajpat Rai Marg or AIIMS, are advised to use the Ring Road instead, it stated. Similarly, those coming from AIIMS or Lodhi Road and heading towards Sarai Kale Khan, Greater Noida, or DND can also take the Ring Road via Lala Lajpat Rai Marg to reach their destination, it added.

Narayana Hrudayalaya Ltd. has gained 46.18% in the last 1 Year

Healthcare Global Enterprises Ltd.

16 Apr 2025

575.50

-3.38%

Hospital stocks in demand; Narayana, HCG hit new high, Yatharth surges 6%

Business Standard

Shares of Hospital firms gained amid rising demand for specialized treatments, including oncology and high-end surgical procedures; this trend contributes to higher ARPOB and overall revenue growth.

Healthcare Global Enterprises Ltd. has gained 58.08% in the last 1 Year

Sanofi Consumer Healthcare India Ltd.

16 Apr 2025

4946.20

0.02%

Dividend, rights issue: Sanofi Consumer, 4 others to remain in focus

Business Standard

Here is the complete list of companies whose shares will trade ex-date on April 17, 2025, along with their key corporate announcements, as per data available on the BSE

Sanofi Consumer Healthcare India Ltd. has gained 31.11% in the last 1 Year

Zydus Lifesciences Ltd.

16 Apr 2025

852.70

0.87%

ZYDUS LIFESCIENCES LIMITED

Buy: Zydus Lifesciences Ltd.

Recommendation Target

Geojit BNP Paribas

Zydus Lifesciences Ltd. is trading below all available SMAs

Apollo Hospitals Enterprise Ltd.

15 Apr 2025

7088.50

-0.76%

Apollo Hospitals eyes acquisitions in North India; 6,000-crore capacity expansion plans underway

Business Line

Plan includes cities such as Noida and Varanasi, and other tier-II towns like Kanpur, while capitalising on surging demand for advanced healthcare

Number of FII/FPI investors increased from 1501 to 1548 in Mar 2025 qtr.

AstraZeneca Pharma India Ltd.

15 Apr 2025

8971.50

2.80%

AstraZeneca India surrenders marketing approval of prostate cancer drug

Business Standard

AstraZeneca Pharma India Ltd on Tuesday said it has surrendered the marketing authorisation of prostate cancer treatment drug Olaparib (Lynparza) 100mg and 150mg in India citing commercial reasons. The company had received marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) on November 17, 2023, AstraZeneca Pharma India said in a regulatory filing. It has now surrendered the marketing authorisation of the indication of Olaparib (Lynparza) 100mg and 150mg, the filing added. "...since the date of receipt of marketing authorisation for the said indications i.e. November 17, 2023, till date, we have never marketed the said indication in India," the company said, adding, "the discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons." The drug is indicated in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with metastatic castration-resistant prostate ..